Cloning and characterization of the prostate-specific membrane antigen promoter
1999; Wiley; Volume: 74; Issue: 3 Linguagem: Inglês
10.1002/(sici)1097-4644(19990901)74
ISSN1097-4644
AutoresDavid M. Good, Paul Schwarzenberger, James A. Eastham, Robert E. Rhoads, Jay D. Hunt, Michael D. Collins, Mark A. Batzer, Chris Theodossiou, Jay K. Kolls, Sidney R. Grimes,
Tópico(s)Xenotransplantation and immune response
ResumoJournal of Cellular BiochemistryVolume 74, Issue 3 p. 395-405 Research Article Cloning and characterization of the prostate-specific membrane antigen promoter† David Good, David Good Gene Therapy Program, School of Medicine, New Orleans, Louisiana 70112 Stanley S. Scott Cancer Center, School of Medicine, New Orleans, Louisiana 70112Search for more papers by this authorPaul Schwarzenberger, Paul Schwarzenberger Gene Therapy Program, School of Medicine, New Orleans, Louisiana 70112 Stanley S. Scott Cancer Center, School of Medicine, New Orleans, Louisiana 70112 Department of Medicine, School of Medicine, New Orleans, Louisiana 70112Search for more papers by this authorJames A. Eastham, James A. Eastham Department of Urology, School of Medicine, Louisiana State University Medical Center, Shreveport, Louisiana 71130Search for more papers by this authorRobert E. Rhoads, Robert E. Rhoads Department of Biochemistry and Molecular Biology, School of Medicine, Louisiana State University Medical Center, Shreveport, Louisiana 71130Search for more papers by this authorJay D. Hunt, Jay D. Hunt Stanley S. Scott Cancer Center, School of Medicine, New Orleans, Louisiana 70112 Department of Biochemistry and Molecular Biology, School of Medicine, New Orleans, Louisiana 70112Search for more papers by this authorMichael Collins, Michael Collins Gene Therapy Program, School of Medicine, New Orleans, Louisiana 70112 Stanley S. Scott Cancer Center, School of Medicine, New Orleans, Louisiana 70112 Department of Medicine, School of Medicine, New Orleans, Louisiana 70112Search for more papers by this authorMark Batzer, Mark Batzer Gene Therapy Program, School of Medicine, New Orleans, Louisiana 70112 Stanley S. Scott Cancer Center, School of Medicine, New Orleans, Louisiana 70112 Department of Pathology, School of Medicine, New Orleans, Louisiana 70112Search for more papers by this authorChris Theodossiou, Chris Theodossiou Gene Therapy Program, School of Medicine, New Orleans, Louisiana 70112 Stanley S. Scott Cancer Center, School of Medicine, New Orleans, Louisiana 70112 Department of Medicine, School of Medicine, New Orleans, Louisiana 70112Search for more papers by this authorJay K. Kolls, Jay K. Kolls Gene Therapy Program, School of Medicine, New Orleans, Louisiana 70112 Stanley S. Scott Cancer Center, School of Medicine, New Orleans, Louisiana 70112 Department of Medicine, School of Medicine, New Orleans, Louisiana 70112 Department of Pediatrics, School of Medicine, New Orleans, Louisiana 70112Search for more papers by this authorSidney R. Grimes, Corresponding Author Sidney R. Grimes [email protected] Department of Biochemistry and Molecular Biology, School of Medicine, Louisiana State University Medical Center, Shreveport, Louisiana 71130 Veterans Administration Medical Center, Shreveport, Louisiana 71101Research Service (151), VA Medical Center, 510 E. Stoner Ave., Shreveport, LA 71101-4295.Search for more papers by this author David Good, David Good Gene Therapy Program, School of Medicine, New Orleans, Louisiana 70112 Stanley S. Scott Cancer Center, School of Medicine, New Orleans, Louisiana 70112Search for more papers by this authorPaul Schwarzenberger, Paul Schwarzenberger Gene Therapy Program, School of Medicine, New Orleans, Louisiana 70112 Stanley S. Scott Cancer Center, School of Medicine, New Orleans, Louisiana 70112 Department of Medicine, School of Medicine, New Orleans, Louisiana 70112Search for more papers by this authorJames A. Eastham, James A. Eastham Department of Urology, School of Medicine, Louisiana State University Medical Center, Shreveport, Louisiana 71130Search for more papers by this authorRobert E. Rhoads, Robert E. Rhoads Department of Biochemistry and Molecular Biology, School of Medicine, Louisiana State University Medical Center, Shreveport, Louisiana 71130Search for more papers by this authorJay D. Hunt, Jay D. Hunt Stanley S. Scott Cancer Center, School of Medicine, New Orleans, Louisiana 70112 Department of Biochemistry and Molecular Biology, School of Medicine, New Orleans, Louisiana 70112Search for more papers by this authorMichael Collins, Michael Collins Gene Therapy Program, School of Medicine, New Orleans, Louisiana 70112 Stanley S. Scott Cancer Center, School of Medicine, New Orleans, Louisiana 70112 Department of Medicine, School of Medicine, New Orleans, Louisiana 70112Search for more papers by this authorMark Batzer, Mark Batzer Gene Therapy Program, School of Medicine, New Orleans, Louisiana 70112 Stanley S. Scott Cancer Center, School of Medicine, New Orleans, Louisiana 70112 Department of Pathology, School of Medicine, New Orleans, Louisiana 70112Search for more papers by this authorChris Theodossiou, Chris Theodossiou Gene Therapy Program, School of Medicine, New Orleans, Louisiana 70112 Stanley S. Scott Cancer Center, School of Medicine, New Orleans, Louisiana 70112 Department of Medicine, School of Medicine, New Orleans, Louisiana 70112Search for more papers by this authorJay K. Kolls, Jay K. Kolls Gene Therapy Program, School of Medicine, New Orleans, Louisiana 70112 Stanley S. Scott Cancer Center, School of Medicine, New Orleans, Louisiana 70112 Department of Medicine, School of Medicine, New Orleans, Louisiana 70112 Department of Pediatrics, School of Medicine, New Orleans, Louisiana 70112Search for more papers by this authorSidney R. Grimes, Corresponding Author Sidney R. Grimes [email protected] Department of Biochemistry and Molecular Biology, School of Medicine, Louisiana State University Medical Center, Shreveport, Louisiana 71130 Veterans Administration Medical Center, Shreveport, Louisiana 71101Research Service (151), VA Medical Center, 510 E. Stoner Ave., Shreveport, LA 71101-4295.Search for more papers by this author First published: 19 July 1999 https://doi.org/10.1002/(SICI)1097-4644(19990901)74:3 3.0.CO;2-0Citations: 18 † This article is a U.S. Government work and, as such, is in the public domain in the United States of America. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Abstract Prostate-specific membrane antigen (PSMA) is a protein that is expressed predominantly in normal prostate epithelial cells and in most adenocarcinomas of the prostate (Cap) and in virtually all Cap metastases. In this article we describe the cloning of a 2-kb human genomic DNA fragment containing the 5' upstream untranslated region of the PSMA gene and present evidence that it provides promoter activity. When the DNA fragment was cloned into transient expression vectors to examine promoter activity, the vectors were functional in promoting expression in several prostate and nonprostate cell lines in transient transfection assays. A 614-bp fragment derived from the 3' end of the 2-kb fragment may represent the minimal PSMA promoter as determined by deletion mutagenesis. The 2-kb fragment compared with the 614-bp fragment provided higher expression levels when using prostate-derived cell lines (DU 145 and LNCaP). The increased transcription using the 2-kb fragment was not as great in non-prostate cell lines. Little or no transcription over basal levels was seen with a 232-bp promoter fragment. When the concentration of dihydrotestosterone was depleted or supplemented in the growth medium, no significant effect was seen on PSMA-promoted transient expression in LNCaP cells, a prostate cell line. J. Cell. Biochem. 74:395–405, 1999. Published 1999 Wiley-Liss, Inc. REFERENCES Abdel-Nabi HH, Ortman-Nabi JA, See W, Lee J, Ireton R, Boileau M, Unger MW, Halverson C. 1990. Clinical experience with intra lymphatic administration of 111In-labelled monoclonal antibody PAY 276 for the detection of pelvic nodal metastases in prostatic carcinoma. Eur J Nucl Med 16: 149–156. Medline Babaian RJ, Sayer J, Podotoff DA, Steelhammer LC, Bhadkamkar VA, Gulfo JV. 1994. Radioimmunoscintigraphy of pelvic lymph nodes with 111indium-labeled monoclonal antibody CYT-356. J Urol 152(6 Pt 1): 1952–1955. Medline Brawer MK. 1995. How to use prostate-specific antigen in the early detection or screening for prostatic carcinoma. CA Cancer J Clin 45: 148–164. Medline Brothman AR, Lesho LJ, Somers KD, Wright GL Jr., Merchant DJ. 1989. Phenotypic and cytogenetic characterization of a cell line derived from primary prostatic carcinoma. Int J Cancer 44: 898–903. Medline Carter RE, Feldman AR, Coyle JT. 1996. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci USA 93: 749–753. Medline Chomczynski P, Sacchi N. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156–159. Medline Douglas TH, Morgan TO, McLeod DG, Moul JW, Murphy GP, Barren R 3rd, Sesterhenn IA, Mostofi FK. 1997. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients. Cancer 80: 107–114. Medline Gittes RF. 1991. Carcinoma of the prostate [see comments]. N Engl J Med 324: 236–245. Medline Grizzle WE, Myers RB, Arnold MM, Srivastava S. 1994. Evaluation of biomarkers in breast and prostate cancer. J Cell Biochem Suppl 19: 259–266. Medline Haseman MK, Reed NL, Rosenthal SA. 1996. Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen. Positron emission tomography and biopsy correlation. Clin Nucl Med 21: 704–713. Medline Heston WD. 1997. Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase. Urology 49(3A suppl): 104–112. Medline Horoszewicz JS, Leong SS, Chu TM, Waisman ZL, Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK, Sandberg AA. 1980. The LNCaP cell line—a new model for studies on human prostate carcinoma. Prog Clin Biol Res 37: 115–132. Medline Horoszewicz JS, Kawinski E, Murphy GP. 1987. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 7: 927–935. Medline Israeli RS, Powell CT, Fair WR, Heston WD. 1993. Molecular cloning of a complementary DNA encoding a prostate specific membrane antigen. Cancer Res 53: 227–230. Medline Israeli RS, Miller WH Jr, Su SL, Powell CT, Fair WR, Samadi DS, Huryk RF, DeBlasio A, Edwards ET, Wise GJ, et al. 1994a. Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res 54: 6306–6310. Medline Israeli RS, Powell CT, Fair WR, Heston WD. 1994b. Expression of the prostate specific membrane antigen. Cancer Res 54: 1807–1811. Medline Israeli RS, Miller WH Jr Su SL, Samadi DS, Powell CT, Heston WD, Wise GJ, Fair WR. 1995. Sensitive detection of prostatic hematogenous tumor cell dissemination using prostate specific antigen and prostate specific membrane-derived primers in the polymerase chain reaction. J Urol 153(3 Pt 1): 573–577. Medline Leek J, Lench N, Maraj B, Bailey A, Carr IM, Andersen S, Cross J, Whelan P, MacLennan KA, Meredith DM, et al. 1995. Prostate-specific membrane antigen: evidence for the existence of a second related human gene. Br J Cancer 72: 583–588. Medline Loop SM, Rozanski TA, Ostenson RC. 1993. Human primary prostate tumor cell line, ALVA-31: a new model for studying the hormonal regulation of prostate tumor cell growth. Prostate 22: 93–108. Medline Maroulakou IG, Anver M, Garrett L, Green JE. 1994. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci USA 91: 11236–11240. Medline Murphy GP. 1995. Radioscintiscanning of prostate cancer. Cancer 75: 1819–1822. Murphy G, Ragde H, Hall MC, Zhao LS, Troncoso P, Pollack A, Chung LW. 1995. Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients. Anticancer Res 15: 1473–1479. Medline Murphy GP, Maguire RT, Rogers B, Partin AW, Nelp WB, Troychak MJ, Ragde H, Kenny GM, Barren RJ 3rd, Bowes VA, Gregorakis AK, Holmes EH, Boynton AL. 1997. Comparison of serum PSMA, PSA levels with results of Cytogen-356 ProstaScint scanning in prostatic cancer patients. Prostate 33: 281–285. Medline O'Keefe DS, Su SL, Bacich DJ, Horiguchi Y, Luo Y, Powell CT, Zandvliet D, Russell PJ, Molloy PL, Nowak NJ, Shows TB, Mullins C, Vonder Haar RA, Fair WR, Heston WDW. 1998. Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim Biophys Acta 1443: 113–127. Medline Rinker-Schaeffer CW, Hawkins AL, Su SL, Israeli RS, Griffin CA, Isaacs JT, Heston WD. 1995. Localization and physical mapping of the prostate-specific membrane antigen (PSM) gene to human chromosome 11. Genomics 30: 105–108. Medline Silver DA, Pellicer I, Fair WR, Heston WDW, Cordon-Cardo C. 1997. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3: 81–85. Medline Su SL, Huang IP, Fair WR, Powell CT, Heston WD. 1995. Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res 55: 1441–1443. Medline Tjoa BA, Erickson SJ, Bowes VA, Ragde H, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Boynton AL, Murphy GP. 1997. Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate 32: 272–278. Medline Troyer JK, Beckett ML, Wright GL. 1995. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 62: 552–558. Medline Wright GL Jr, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R. 1996. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48: 326–334. Medline Wynant GE, Murphy GP, Horoszewicz JS, Neal CE, Collier BD, Mitchell E, Purnell G, Tyson I, Heal A, Abdel-Nabi H, et al. 1991. Immunoscintigraphy of prostatic cancer: preliminary results with 111In-labeled monoclonal antibody 7E11-C5.3 (CYT-356). Prostate 18: 229–241. Medline Zhau HE, Pisters LL, Kenny G, Barren R 3rd, Erickson S, Tjoa B, Boynton A, Holmes E, Gilbaugh J, Douglas T. 1994. Biomarkers associated with prostate cancer progression. J Cell Biochem Suppl 19: 208–216. Medline Citing Literature Volume74, Issue31 September 1999Pages 395-405 ReferencesRelatedInformation
Referência(s)